Cardinal Health (CAH) 2026 Global Healthcare Conference summary

Performance highlights and growth drivers

• All five operating segments delivered double-digit earnings growth in 2026, with robust cash flow and strong volume, especially in specialty and generics, though future growth is expected to normalize.

• Specialty segment saw 25% growth, driven by M&A and new customer wins, but such outsized gains are not expected to repeat at the same rate.

• Inorganic investments, including the ADS acquisition and recent deals with Strive and AdaptHealth's diabetes segment, are expected to support future growth, though at a more moderate pace.

• The GMPD segment benefited from a tariff refund, but core growth remained strong even when excluding this one-time event.

• Cash flow performance was a standout, with the company already 90% toward its $10 billion target, exceeding expectations.

Strategic execution and industry dynamics

• Strategic review and resegmentation over the past three years have validated the current approach, with synergies from acquisitions exceeding expectations.

• The MSO (managed services organization) strategy remains a high priority, with stable platforms in oncology, urology, and GI, and ongoing bolt-on acquisitions.

• Customer renewals, such as the long-term Kroger contract, are now seen as routine, reflecting a stable, low-churn environment.

• Industry contracts have evolved to address mix changes, with utilization requirements embedded to manage profitability across product categories.

• Specialty and higher-margin businesses are growing faster than generics, shifting the overall business mix.

Operational focus and future outlook

• The at-Home Solutions business is focused on small, high-value products delivered via mail order, leveraging automation and freight scale, and avoiding in-home patient services.

• The AdaptHealth diabetes acquisition is expected to close in the second half of 2027, while Strive has already closed, both enhancing presence in key therapeutic areas.

• Only 35% of eligible patients currently use CGMs, indicating significant growth potential in diabetes care.

• GMPD has turned around from losses, with growth driven by Cardinal Health brand volume and simplification, though commodity costs remain a headwind.

• No major new deals are expected to close before the end of fiscal 2027, but the acquisition pipeline remains robust.